Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth B Gordon

Showing results (81-90 of 136) with videos related to

Pageof 14
Sort By:
Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.
Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
The Journal of Investigative Dermatology|June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 StudyKenneth B Gordon, April W Armstrong, Peter Foley, et al.
The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
The Journal of Investigative Dermatology|June 27, 2024
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2Andrew Blauvelt, Kenneth B Gordon, Richard G Langley, et al.
JAMA Dermatology|March 9, 2016
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical TrialsApril W Armstrong, Charles W Lynde, Sandy R McBride, et al.
Journal of the American Academy of Dermatology|October 25, 2003
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyAlice B Gottlieb, Thomas B Casale, Ellen Frankel, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
Pageof 14

Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.
Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
The Journal of Investigative Dermatology|June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 StudyKenneth B Gordon, April W Armstrong, Peter Foley, et al.
The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
The Journal of Investigative Dermatology|June 27, 2024
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2Andrew Blauvelt, Kenneth B Gordon, Richard G Langley, et al.
JAMA Dermatology|March 9, 2016
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical TrialsApril W Armstrong, Charles W Lynde, Sandy R McBride, et al.
Journal of the American Academy of Dermatology|October 25, 2003
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyAlice B Gottlieb, Thomas B Casale, Ellen Frankel, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
Pageof 14